Quick Takeaways
- BIOTECHNOLOGY VALUE FUND L P filed SCHEDULE 13G/A for Avalo Therapeutics, Inc. Common Stock, $0.001 par value per share (AVTX).
- Disclosed ownership: 10%.
- Date of event: 30 Sep 2025.
Quoteable Key Fact
"BIOTECHNOLOGY VALUE FUND L P disclosed 10% ownership in Avalo Therapeutics, Inc. Common Stock, $0.001 par value per share (AVTX) on 30 Sep 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 5.5% | 806,414 | 0 | 806,414 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| BVF I GP LLC | 5.5% | 806,414 | 0 | 806,414 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| BIOTECHNOLOGY VALUE FUND II LP | 4% | 580,975 | 0 | 580,975 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| BVF II GP LLC | 4% | 580,975 | 0 | 580,975 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| Biotechnology Value Trading Fund OS LP | 0.3% | 40,633 | 0 | 40,633 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| BVF Partners OS Ltd. | 0.3% | 40,633 | 0 | 40,633 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| BVF GP HOLDINGS LLC | 9.5% | 1,387,389 | 0 | 1,387,389 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| BVF PARTNERS L P/IL | 10% | 1,458,151 | 0 | 1,458,151 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| BVF INC/IL | 10% | 1,458,151 | 0 | 1,458,151 | /s/ Mark N. Lampert | Mark N. Lampert, Authorized Signatory | |
| LAMPERT MARK N | 10% | 1,458,151 | 0 | 1,458,151 | /s/ Mark N. Lampert | Mark N. Lampert |